NeuroSense Therapeutics Ltd. has been granted a conditional extension for its listing on the Nasdaq, as per a notice received on November 11, 2024. The extension is contingent upon the company providing a detailed public disclosure by December 18, 2024, outlining the measures taken to comply with Nasdaq's minimum stockholders' equity requirement of $2.5 million. This follows a previous notice from June 21, 2024, where NeuroSense was found non-compliant with the equity rule. The company had presented a plan to regain compliance during a hearing on August 1, 2024, which led to an initial extension until October 31, 2024. The latest report will be incorporated into the company's existing SEC registration statements. NeuroSense also cautions that forward-looking statements in the report are subject to risks and uncertainties, and actual events may differ materially.

NeuroSense Therapeutics Ltd. has been granted a conditional extension for its listing on the Nasdaq, as per a notice received on November 11, 2024. The extension is contingent upon the company providing a detailed public disclosure by December 18, 2024, outlining the measures taken to comply with Nasdaq's minimum stockholders' equity requirement of $2.5 million. This follows a previous notice from June 21, 2024, where NeuroSense was found non-compliant with the equity rule. The company had presented a plan to regain compliance during a hearing on August 1, 2024, which led to an initial extension until October 31, 2024. The latest report will be incorporated into the company's existing SEC registration statements. NeuroSense also cautions that forward-looking statements in the report are subject to risks and uncertainties, and actual events may differ materially.